Gene · 9113
Papers3,081
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
641 to 660 of 3,081
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting the Hippo Pathway in Gastric Cancer and Other Malignancies in the Digestive System: From Bench to Bedside. | Biomedicines | 2022 | 36289774 | PubTator, text mining | PubMed |
| LncRNA surfactant associated 1 activates large tumor suppressor kinase 1/Yes-associated protein pathway via modulating hypoxic exosome-delivered miR-4766-5p to inhibit lung adenocarcinoma metastasis. | Int J Biochem Cell Biol | 2022 | 36283586 | PubTator, text mining | PubMed |
| The clinical prognostic value of lncRNA FOXP4-AS1 in cancer patients: A meta-analysis and bioinformatics analysis based on TCGA datasets. | Medicine (Baltimore) | 2022 | 36281152 | PubTator, text mining | PubMed |
| Salt-inducible kinase 1 deficiency promotes vascular remodeling in pulmonary arterial hypertension via enhancement of yes-associated protein-mediated proliferation. | Heliyon | 2022 | 36276742 | PubTator, text mining | PubMed |
| Skin cell-derived extracellular vesicles: a promising therapeutic strategy for cutaneous injury. | Burns Trauma | 2022 | 36267497 | PubTator, text mining | PubMed |
| A novel necroptosis-related lncRNA signature predicts the prognosis and immune microenvironment of hepatocellular carcinoma. | Front Genet | 2022 | 36267408 | PubTator, text mining | PubMed |
| Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement. | Mater Today Bio | 2022 | 36267139 | PubTator, text mining | PubMed |
| SHANK family on stem cell fate and development. | Cell Death Dis | 2022 | 36257935 | PubTator, text mining | PubMed |
| Spatial modeling reveals nuclear phosphorylation and subcellular shuttling of YAP upon drug-induced liver injury. | Elife | 2022 | 36255405 | PubTator, text mining | PubMed |
| miR21 modulates the Hippo signaling pathway via interference with PP2A Bβ to inhibit trophoblast invasion and cause preeclampsia. | Mol Ther Nucleic Acids | 2022 | 36250210 | PubTator, text mining | PubMed |
| Identification and validation of ferroptosis-related lncRNA signature as a prognostic model for skin cutaneous melanoma. | Front Immunol | 2022 | 36248853 | PubTator, text mining | PubMed |
| Comprehensive analysis of liquid-liquid phase separation-related genes in prediction of breast cancer prognosis. | Front Genet | 2022 | 36246644 | PubTator, text mining | PubMed |
| The Hippo-Yki Signaling Pathway Positively Regulates Immune Response against Vibrio Infection in Shrimp. | Int J Mol Sci | 2022 | 36233199 | PubTator, text mining | PubMed |
| Prognostic and Immunological Role of STK38 across Cancers: Friend or Foe? | Int J Mol Sci | 2022 | 36232893 | PubTator, text mining | PubMed |
| Liquid-Liquid Phase Separation in Cardiovascular Diseases. | Cells | 2022 | 36231002 | PubTator, text mining | PubMed |
| Mechanosensitive Ion Channel PIEZO1 Signaling in the Hall-Marks of Cancer: Structure and Functions. | Cancers (Basel) | 2022 | 36230880 | PubTator, text mining | PubMed |
| A Review and In Silico Analysis of Tissue and Exosomal Circular RNAs: Opportunities and Challenges in Thyroid Cancer. | Cancers (Basel) | 2022 | 36230649 | PubTator, text mining | PubMed |
Using Patient-Derived Xenograft (PDX) Models as a 'Black Box' to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial. | Cancers (Basel) | 2022 | 36230574 | PubTator, text mining | PubMed |
| Molecular Classification of Hepatocellular Carcinoma Using Wnt-Hippo Signaling Pathway-Related Genes. | Cancers (Basel) | 2022 | 36230503 | PubTator, text mining | PubMed |
| LncmiRHG-MIR100HG: A new budding star in cancer. | Front Oncol | 2022 | 36212400 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9113/papers?page=33